Navigation Links
Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
Date:3/30/2009

LA JOLLA, Calif., March 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that the United States District Court of the Southern District of New York dismissed proceedings filed in February 2005 by former stockholders of Axonyx Inc. ("Axonyx") against Axonyx and several of Axonyx's former directors and officers. TorreyPines acquired Axonyx Inc. in 2006. The plaintiffs alleged that the defendants made misleading statements related to Phase III clinical trials of Axonyx's drug candidate, phenserine. The complaint was dismissed in its entirety. In January 2009 a related outstanding derivative action against Axonyx was discontinued by the New York Supreme Court.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, and xerostomia. The company currently has three clinical stage product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com.

This press release contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company contact:                                Investor contact:
    Paul Schneider                                  Rhonda Chiger
    TorreyPines Therapeutics, Inc.                  Rx Communications Group
    858-623-5665 x 125                              (917) 322-2569
    pschneider@TPTXinc.com                          rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ev3 and FoxHollow Announce Date for Special Meeting of FoxHollow Stockholders to Vote on Proposed Merger
2. Micrus Endovascular to Webcast Fiscal 2007 Annual Meeting of Stockholders
3. Kyphon Stockholders Approve Merger with Medtronic
4. Paramount Stockholders Approve Acquisition of Chem Rx
5. Nabi Biopharmaceuticals Stockholders Approve Asset Sale
6. Halozyme Therapeutics Amends Stockholder Rights Plan
7. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
8. VaxGen Addresses MPM Claims in Letter to Stockholders
9. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
10. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
11. Special Stockholders Meeting to Elect Directors Set for March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... G. Fujimoto, Ph.D ., the Elihu Thomson Professor of Electrical Engineering and Computer ... Research Award winner. Presented annually, the award recognizes an individual who has ...
(Date:7/20/2017)... ... , ... VIC Technology Venture Development™ (VIC™), is pleased to announce ... addition continues to strengthen and diversify VIC’s board. , "We are excited to have ... highly accomplished business executive with a broad range of experience directly relevant to VIC ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... solution to make clinical trial sites and study participants truly unified. TrialKit, a ... compliant (FDA 21 CFR Part 11) research studies entirely on mobile devices. With ...
(Date:7/18/2017)... , ... July 18, 2017 , ... ... the United States Patent and Trademark Office for its Patent Applications 14/858,857 and ... Office’s allowances of these patent applications further expand the protection of G-CON’s R&D ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):